In yesterday’s Wall Street session, Atara Biotherapeutics Inc. (NASDAQ:ATRA) shares traded at $2.18, up 11.79% from the previous session.
As of this writing, 9 analysts cover Atara Biotherapeutics Inc. (NASDAQ:ATRA). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $31.00 and a low of $2.00, we find $20.00. Given the previous closing price of $1.95, this indicates a potential upside of 925.64 percent. ATRA stock price is now 7.71% away from the 50-day moving average and -35.92% away from the 200-day moving average. The market capitalization of the company currently stands at $191.60M.
There are 2 analysts who have given it a hold rating, whereas 5 have given it a buy rating. Brokers who have rated the stock have averaged $16.27 as their price target over the next twelve months.
With the price target reduced from $8 to $3, Citigroup Downgraded its rating from Neutral to Sell for Atara Biotherapeutics Inc. (NASDAQ: ATRA).
In other news, Touchon Pascal, President and CEO sold 14,291 shares of the company’s stock on Jun 27. The stock was sold for $23,723 at an average price of $1.66. Upon completion of the transaction, the President and CEO now directly owns 706,671 shares in the company, valued at $1.54 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 16, President and CEO Touchon Pascal sold 29,766 shares of the business’s stock. A total of $60,633 was realized by selling the stock at an average price of $2.04. This leaves the insider owning 720,962 shares of the company worth $1.57 million. Insiders disposed of 157,543 shares of company stock worth roughly $0.34 million over the past 1 year. A total of 1.50% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ATRA stock. A new stake in Atara Biotherapeutics Inc. shares was purchased by UBS ASSET MANAGEMENT AMERICAS INC during the first quarter worth $235,000. PROFUND ADVISORS LLC invested $228,000 in shares of ATRA during the first quarter. In the first quarter, SHELL ASSET MANAGEMENT CO acquired a new stake in Atara Biotherapeutics Inc. valued at approximately $117,000. HARBOR CAPITAL ADVISORS, INC. acquired a new stake in ATRA for approximately $109,000. POINT72 ASSET MANAGEMENT, L.P. purchased a new stake in ATRA valued at around $59,000 in the second quarter. In total, there are 217 active investors with 103.98% ownership of the company’s stock.
Tuesday morning saw Atara Biotherapeutics Inc. (NASDAQ: ATRA) opened at $1.9600. During the past 12 months, Atara Biotherapeutics Inc. has had a low of $1.45 and a high of $8.85. As of last week, the company has a debt-to-equity ratio of 0.01, a current ratio of 3.30, and a quick ratio of 3.20. The fifty day moving average price for ATRA is $2.0160 and a two-hundred day moving average price translates $3.3951 for the stock.
The latest earnings results from Atara Biotherapeutics Inc. (NASDAQ: ATRA) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$0.72, missing analysts’ expectations of -$0.39 by -0.33. This compares to -$0.87 EPS in the same period last year. The company reported revenue of $1.23 million for the quarter, compared to $7.31 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -83.24 percent. For the current quarter, analysts expect ATRA to generate $4.52M in revenue.
Atara Biotherapeutics Inc.(ATRA) Company Profile
Atara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA2271 and ATA3271 to treat mesothelin; and ATA3219 for the treatment of B-cell malignancies, as well as ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. The company was incorporated in 2012 and is headquartered in Thousand Oaks, California.
